• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Researchers find new target to combat lung disease

Bioengineer by Bioengineer
November 24, 2021
in Biology
Reading Time: 2 mins read
0
Professor Phil Hansbro
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Research led by the Centenary Institute and University of Technology Sydney (UTS) has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment for chronic obstructive pulmonary disease (COPD).

Professor Phil Hansbro

Credit: Supplied by Centenary UTS Centre for Inflammation

Research led by the Centenary Institute and University of Technology Sydney (UTS) has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment for chronic obstructive pulmonary disease (COPD).

An inflammatory lung disease that makes it hard to breathe, COPD is often caused by smoking tobacco products or inhaling air pollution. It is the third most common cause of death in the world.

In the pre-clinical study, the researchers found elevated levels of microRNA-21 in experimental COPD models involving mice. Use of a microRNA-21 inhibitor (antagomir-21) as a therapeutic treatment was shown to reduce inflammation and improve lung capacity and function in these models.

The researchers said antagomir-21 both reduced microRNA-21 expression and also suppressed the influx of inflammatory cells – macrophages, neutrophils and lymphocytes – into the airways and lungs. Lung cytokine production, that amplifies inflammatory responses, was also inhibited through use of antagomir-21.

Professor Phil Hansbro, the study’s senior author and Director of the Centenary UTS Centre for Inflammation, said that their findings offered up a completely new understanding of COPD.

“MicroRNA-21 is a common molecule that is expressed in most cells in the human body and regulates many critical biological processes. Our findings demonstrate, however, that microRNA-21 levels increase when it comes to COPD,” said Professor Hansbro.

“We believe that the development of new drugs that inhibit microRNA-21 may offer up an entirely new therapeutic approach when it comes to COPD treatment.”

Professor Hansbro said that the findings may address the limited effectiveness that current therapies have in controlling COPD or halting its progression.

“The development of effective COPD treatments has been hampered by a lack of understanding of the disease’s underlying mechanisms. Our data defines microRNA-21 as a novel therapeutic target and its inhibitors as a potential new treatment for this major, currently intractable lung disease.”

The research is published in the journal Science Translational Medicine: A microRNA-21–mediated SATB1/S100A9/NF-kB axis promotes chronic obstructive pulmonary disease pathogenesis.



Journal

Science Translational Medicine

DOI

10.1126/scitranslmed.aav7223

Method of Research

Experimental study

Subject of Research

Animals

Article Title

A microRNA-21–mediated SATB1/S100A9/NF-B axis promotes chronic obstructive pulmonary disease pathogenesis

Article Publication Date

24-Nov-2021

COI Statement

P.M.H. has consulted and/or worked with Sanofi, AstraZeneca, Allakos, Pharmakea, Ionis, Cincera, NextScience, MucPharm, Lateral Pharma, and Gertrude, but none are related to the current study. All other authors declare that they have no competing interests.

Share12Tweet8Share2ShareShareShare2

Related Posts

Engineered Gut Bacteria Enhance Survival Rates in Colorectal Cancer Patients

Engineered Gut Bacteria Enhance Survival Rates in Colorectal Cancer Patients

September 22, 2025
blank

Unveiling Toxocara canis Excretory-Secretory Products’ Impact

September 22, 2025

Oxaloacetate Sensing Boosts Innate Flu Defense

September 22, 2025

Nasal Staph Affects Mice Mood by Hormone Breakdown

September 22, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    68 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unraveling Copper’s Redox Role in Ullmann Reactions

Koala Stress Levels Connected to Increased Disease Risk

Metabolic Markers Identified as Potential Predictors of Breast Cancer Risk in High-Risk Women

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.